Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oil Well Update

29 Oct 2008 07:00

RNS Number : 8905G
ViaLogy PLC
29 October 2008
 



 ViaLogy Plc ("ViaLogy" or "the Company")

Oil Well Update

London29 October. ViaLogy PLC (AIM: VIY), the AiM-listed technology company,  announced today that drilling operations on the High Lonesome Ranch Nancy Hundley #1 in McMullen County, Texas by Atascosa Exploration LLC, of San Antonio, Texas, using ViaLogy's Quantum RD technology, were concluded on 26 October, 2008.  The well was drilled to a total depth of 6,080 feet.

The QuantumRD analysis located a significant oil reservoir. However, post-drilling analysis indicated small faults in the targeted oil trap. These faults are within the margin of error for 3D seismic visibility. ViaLogy performed its analysis without being provided with this information and, therefore, did not allow for anomalies which could probably have identified the faults. Such faults made the economic extraction of oil unviable, as they reduced a large reservoir to many small reservoirs, significantly increasing the extraction cost per barrel. Accordingly, the well has been plugged by Atascosa. However, the data gained from this well will be important for the siting of future wells.

 

"Atascosa is not at all discouraged by this development" said Atascosa CEO John Mullins. "The drilling outcome was a result of our not informing ViaLogy of the problem the raw data ultimately caused. The QuantumRD analysis was correct based on available data. Atascosa has committed to drill at least three separate prospects using QuantumRD and remains committed to that effort, which will be at an additional cost to Atascosa of $2-3 million dollars. ViaLogy will continue to receive at no cost a 5% Back-In-After-Pay-Out working interest in the first well successfully drilled and completed on each prospect, with the right to participate in subsequent wells under a standard operating agreement." 

ViaLogy CEO, Robert Dean, said: "The ViaLogy geoseismic team located a significant oil reservoir as predicted, and we consider this a positive milestone in earning proof of concept for QuantumRD. We are moving ahead with Atascosa within 30 days to begin drilling the next two prospects, which we expect will conclusively validate QuantumRD as a breakthrough oil discovery tool." 

Enquiries:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Nominated Advisor (Seymour Pierce) Mark Percy +44 (0) 20-7107-8000

Stockbroker - St. Helen's Capital PLC +44 (0) 20-7628 5582 

PR Consultants - Redleaf Communications  Emma Kane / Samantha Robbins +44 (0) 20-7566 6700 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLBRBDGLSDGGII
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.